Felbinac

Summary

Felbinac (CHEMBL413965) is an approved small-molecule non-steroidal anti-inflammatory drug (ATC M02AA08); indicated across 6 conditions including neoplasm and acute kidney injury.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: M02AA08
• Indications: 6 conditions
• Chemistry: 212.24 Da · C14H12O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL413965
Name	Felbinac
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3332
ChEBI	CHEBI:31597
ATC	M02AA08
Molecular formula	C14H12O2
Molecular weight	212.24
InChIKey	QRZAKQDHEVVFRX-UHFFFAOYSA-N

SMILES: C1=CC=C(C=C1)C2=CC=C(C=C2)CC(=O)O

IUPAC name: 2-(4-phenylphenyl)acetic acid

ChEBI definition: A monocarboxylic acid in which one of the α-hydrogens is substituted by a biphenyl-4-yl group. An active metabolite of fenbufen, it is used as a topical medicine to treat muscle inflammation and arthritis.

Pharmacological roles (ChEBI): non-steroidal anti-inflammatory drug.

Also known as: CL 83,544, CL-83544, Dolinac, Felbinac, Felbinac ethyl, Felbinaco, L-141, LJC 10,141, LJC-10141, Ly-61017, Napageln, NSC-16284

Parent form; salt/anhydrous children: CHEMBL141152

Patent coverage: 3,494 distinct patent families (12,526 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Prelamin-A/C, ATP-binding cassette sub-family C member 4, Thyrotropin receptor, Prostaglandin G/H synthase 1, Lysosomal alpha-glucosidase, Huntingtin.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 8 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PTGS1	6.05	IC50	894	nM	CHEMBL_ACT_7663146
LMNA	5.6	Potency	2512	nM	CHEMBL_ACT_3646463
TSHR	5.3	Potency	5012	nM	CHEMBL_ACT_3920256
TSHR	5.3	Potency	5012	nM	CHEMBL_ACT_4618532
ABCC4	5.09	IC50	8200	nM	CHEMBL_ACT_18130914

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	2	MONDO:0005070	MONDO:0004992
acute kidney injury	1	MONDO:0002492	HP:0001919

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).